GHK-Cu 0.5% | Minoxidil 5%

Route: Topical scalp application.

Apply the prescribed volume to clean, dry scalp in the areas of hair thinning or loss, typically once or twice daily as directed. Part the hair and apply directly to the scalp (not the hair). Gently spread with fingertips; do not rinse off. Wash hands after application. Allow to dry before styling. Avoid contact with eyes or mucous membranes. As with all minoxidil preparations, do not apply to broken or irritated scalp. Do not use on other body areas unless specified by the prescriber.

All dosing is prescriber-determined. General guidance based on established minoxidil and GHK-Cu clinical experience:

• Typical frequency: Apply once to twice daily to affected scalp areas.
• Initial response in hair counts or reduced shedding may begin at 8–12 weeks; maximum effect for minoxidil typically requires at least 4–6 months of continuous use.
• Minoxidil's benefits are not permanent; hair shedding typically resumes within weeks of discontinuation and original hair density is lost within approximately 12 months of stopping.
• Duration of treatment is ongoing and prescriber-directed.

• GHK-Cu 0.5%: GHK-Cu modulates gene expression to stimulate production of collagen I, glycosaminoglycans, and growth factors (bFGF, VEGF analogs) in the perifollicular dermis, supporting the extracellular matrix scaffold that anchors hair follicles. It reduces NF-κB-mediated scalp inflammation (elevated IL-6, TNF-α) associated with androgen-driven miniaturization, and may promote epidermal basal cell stemness. Copper, delivered in a bioavailable non-toxic form via the GHK chelate, is an essential cofactor for lysyl oxidase, the enzyme that cross-links collagen and elastin in the follicular sheath.
• Minoxidil 5%: A prodrug converted by sulfotransferase SULT1A1 in hair follicle outer root sheath cells to the active metabolite minoxidil sulfate. Minoxidil sulfate opens ATP-sensitive potassium channels (KATP) in vascular smooth muscle and follicular cells, causing hyperpolarization and vasodilation, increasing perifollicular microcirculation and nutrient and oxygen delivery. It also stimulates prostaglandin E2 (PGE2) synthesis via COX-1 activation, upregulating the PGE2 receptor in dermal papilla cells — the most upregulated target of the β-catenin growth signaling pathway — thereby maintaining follicles in the anagen (active growth) phase. Minoxidil may additionally downregulate 5α-reductase type 2 gene expression in scalp cells, contributing a modest anti-androgenic effect.

Clinical Context: This combination is used in prescriber-directed therapy for androgenetic alopecia (AGA) and related hair loss conditions. Minoxidil 5% topical is FDA-approved for male pattern hair loss (AGA) and is widely used off-label in female AGA. GHK-Cu is incorporated to address the perifollicular dermal environment, reduce scalp inflammation, and support the extracellular matrix that is disrupted in chronic AGA.

Monitoring Considerations:

• Evaluate hair shedding response and hair count at 3–6 months; initial shedding increase at weeks 4–8 (telogen effluvium triggered by new anagen induction) is normal and transient.
• Scalp and skin tolerability (irritation, scaling, contact dermatitis) should be assessed; if persistent irritation occurs, consider vehicle adjustment.
• Blood pressure monitoring is generally not required with topical minoxidil at 5% as systemic absorption is low, but symptomatic hypotension should prompt reassessment — particularly in patients also using systemic antihypertensives.
• Benefits of minoxidil are not maintained after discontinuation; counsel patients on long-term adherence.

Contraindications:

• Known hypersensitivity to minoxidil, GHK-Cu, propylene glycol (common vehicle), or any excipient.
• Topical minoxidil is not indicated in pediatric patients without specialist guidance.
• Pregnancy: minoxidil is associated with fetal risk in animal studies; avoid during pregnancy unless benefit clearly outweighs risk.

Warnings & Precautions:

• Topical minoxidil has some systemic absorption; use with caution in patients with cardiovascular disease or poorly controlled hypertension.
• Contact dermatitis and scalp irritation are common minoxidil side effects; may relate to propylene glycol in vehicle — consider propylene glycol–free formulations if irritation persists.
• Unwanted facial or body hair growth (hypertrichosis) can occur with chronic scalp application and systemic absorption.
• Do not apply to abraded, sunburned, or inflamed scalp.

Drug Interactions:

• Systemic antihypertensives: additive hypotensive effects possible with topical minoxidil systemic absorption; monitor blood pressure.
• Guanethidine: concurrent use with minoxidil may produce severe orthostatic hypotension.
• Topical corticosteroids, tretinoin: may enhance minoxidil skin absorption; monitor closely.

Common Side Effects: Local scalp irritation, pruritus, dryness, and flaking (primarily minoxidil/vehicle related). Hypertrichosis (unwanted hair in non-treatment areas). Transient increased shedding during first 4–8 weeks. Rare: facial edema, headache, tachycardia, or dizziness from systemic absorption.

Store at controlled room temperature (20–25°C / 68–77°F). Protect from light and heat. Keep container tightly closed. Do not freeze. Keep away from open flame (vehicle may be alcohol-based and flammable). Keep out of reach of children. Use before the beyond-use date (BUD) assigned by Genesis Compounding on the prescription label.

Why is GHK-Cu added to minoxidil for hair loss?

Minoxidil addresses hair follicle vasodilation and anagen prolongation, while GHK-Cu works at a complementary level — supporting the perifollicular extracellular matrix, reducing scalp inflammation, and providing the copper cofactor needed for collagen cross-linking in the follicular sheath. Together, they address both the vascular and structural components of hair follicle health.

When should I expect results?

Some patients notice reduced shedding within 8–12 weeks. Visible hair count improvements typically require at least 4–6 months of consistent daily use. An initial shedding increase during the first 4–8 weeks is normal and represents old telogen hairs being displaced by new anagen growth — it is not a sign of treatment failure.

Do I need to use this indefinitely?

Minoxidil's benefits are not permanent; most patients begin to lose newly regrown hair within weeks of stopping treatment, with pre-treatment density returning over approximately 12 months. Long-term use is typically required to maintain benefit. Your prescriber will guide ongoing treatment planning.

Is this combination FDA-approved?

Minoxidil 5% topical is FDA-approved for male androgenetic alopecia as a standalone product. The combination with GHK-Cu in a single formulation requires compounding and is not FDA-approved as a compounded product. Genesis Compounding prepares this as a prescription-only, patient-specific 503A preparation.

Can I use this if I have heart disease or take blood pressure medications?

Topical minoxidil has low but measurable systemic absorption. Use with caution in patients with cardiovascular disease or on antihypertensives, and report any symptoms of dizziness, chest discomfort, or swelling to your prescriber promptly.